. Contract Research Organizations (CROs) are much more than mere companies that offer support to the pharmaceutical or biotechnology industries in the form of research services outsourced on a [...]
. New Alternative Models (NAMs) for research, which include in vitro cellular models, are destined to transform the future of biomedical research. Regulatory agencies implement laws concerning animal use [...]
Metabolic (dysfunction) associated fatty liver disease (MAFLD) is the most common chronic liver disease, affecting around 25 % of the world population. It is characterized by an accumulation of [...]
Liver models to test new drugs based on 2D cell culture of primary hepatocytes and the use of experimental animal models are slow, costly, and have significant biases. BeCytes [...]
Drug-induced liver injury (DILI) has fatal consequences, both personally and economically. Its health impact ranges from mild liver enzyme elevation to severe liver failure. In the drug development process, [...]
Regulatory agencies, such as the Food and Drug Administration (FDA), are moving towards reducing animal testing and encouraging the use of New Alternative Methodologies (NAMs) in pharmaceutical research. NAMs [...]
Parc Científic de Barcelona (PCB), Tower I, Baldiri Reixac 4-8, 08028 Barcelona, Spain
Cytes Biotechnologies S.L. within the framework of the Export Initiation Program of ICEX, has had the support of ICEX and with the co-financing of the European FEDER fund. The purpose of this support is to contribute to the international development of the company and its environment.
Privacy Policy | Terms and Conditions | Data Protection Policy | Cookies Policy | All Right Reserved Copyright © 2026
